Together, the evidence seems to suggest that Bcl-xL still holds promise as a target in the anti-senescence treatment of PD, but the concentration of Bcl-xL specific senolytics and Bcl-xL fragmentation potential needs to be taken into consideration. Here, BCL2L1 is linked to Parkinson disease.